Efficacy, safety, and tolerability of rituximab in multiple sclerosis patients who were non-responders to baseline disease-modifying drugs (DMD).
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2015
At a glance
- Drugs Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2015 New trial record